Whitepaper: The AI buying guide for BD&L executives
AI is already transforming how leading organizations identify, evaluate, and close deals, but not all AI platforms are built for BD&L.
AI is already transforming how leading organizations identify, evaluate, and close deals, but not all AI platforms are built for BD&L.
Learn how Incite partnered with Vibe Bio to accelerate sarcoma drug discovery with unbiased ranking and AI-powered compound analysis.
Learn how Orphan Therapeutics Accelerator uses Vibe Bio for rare disease due diligence, pipeline and competitive analysis, and in-licensing strategy.
The Orphan Therapeutics Accelerator, a non-profit biotech organization focused on completing development and commercializing therapies for ultra-rare conditions